Immunitybio Inc
NASDAQ:IBRX
Operating Margin
Immunitybio Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Immunitybio Inc
NASDAQ:IBRX
|
2.6B USD |
-1 004%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
337.9B USD |
30%
|
|
| US |
|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 834%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
165.8B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
141.4B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122.6B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
130.4B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
61.9B USD |
29%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
Immunitybio Inc
Glance View
ImmunityBio, Inc., born from the vision of tackling some of the most stubborn challenges in modern medicine, operates at the cutting edge of biotechnology. Founded by Dr. Patrick Soon-Shiong, a renowned physician and surgeon, the company is driven by the mission to develop innovative immunotherapies that unlock the potential of the human immune system to fight cancer and infectious diseases. At the heart of ImmunityBio’s operations is their proprietary platform, designed to activate multiple components of the immune system, thereby aiming to enhance the body’s ability to combat malignant cells and improve patient outcomes. The company's diverse portfolio includes tumor-targeting antibodies, natural killer (NK) cell therapies, and vaccine platforms, underscoring its commitment to addressing diseases from multiple angles. ImmunityBio generates revenue by taking these biotechnology innovations from the lab to the marketplace. Partnerships and collaborations with larger pharmaceutical companies play a significant role in advancing their pipeline and bringing therapies to market. For example, strategic alliances help streamline the extensive and costly clinical trial process, enhancing the speed and efficiency of drug development. Additionally, the company is invested in establishing licensing agreements, which allow them to leverage their proprietary technology in collaboration with other industry players. Through these initiatives, ImmunityBio not only seeks to accelerate the commercialization of its therapies but also aims to carve out a sustainable financial path in the ever-competitive healthcare landscape.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Immunitybio Inc's most recent financial statements, the company has Operating Margin of -1 003.8%.
You don't have any saved screeners yet